CA-ANDERSEN-TAX
Claritas Tax Limited, der er et af Andersen Globals samarbejdsfirmaer i Storbritannien med hjemsted i Birmingham, har åbnet et nyt kontor i Deansgate i centrum af Manchester. Det betyder, at Andersen Global nu er repræsenteret seks steder i Storbritannien via sine medlems- og samarbejdsfirmaer.
“Nu til dags er det vigtigere end nogensinde før, at virksomheder har let adgang til kvalitetsrådgivning i Storbritanniens dynamiske politiske og erhvervsmæssige miljø. Tilføjelsen af endnu en lokalitet i regionen øger vores eksisterende kapaciteter og vil give os mulighed for fortsat at levere sømløs, uovertruffen service,” udtalte Mark Vorsatz, bestyrelsesformand for Andersen Global og administrerende direktør for Andersen Tax LLC.
Claritas Tax Limited, der blev grundlagt i 2012, har en kundebase, der spænder fra iværksætter-, privatejede, venturekapital- og private equity-ejede virksomheder, børsnoterede selskaber og interessenter. Claritas leverer en bred vifte af skatterådgivningstjenester, herunder alle aspekter af fusioner og virksomhedsovertagelser og transaktionsskatter, forskning og udvikling og intellektuelle ejendomskrav, aktionær- og virksomhedsomstruktureringer, opløsning af fusioner, aktieordninger og værdiansættelse af aktier, samt overholdelse af personlig og virksomhedsmæssig skattelovgivning. Virksomheden annoncerede i december sidste år sit samarbejde med Andersen Global og ledes af direktør og grundlægger Iain Wright.
Kontoret i Manchester vil fortsætte firmaets fokus på rådgivnings- og compliance-tjenester og skal ledes af partner Matt Hodgson. Før han sluttede sig til Claritas, var Matt Associate Partner hos EY.
Iain kommenterede, “Matt er en utroligt dygtig skatterådgiver, der leverer fantastisk kommerciel fokus og teknisk ekspertise til sine kunder. Manchester og den større nordvestlige region er en utrolig dynamisk økonomi, og jeg er meget begejstret for, at vores 2. kontor vil være beliggende der.”
Andersen Global er en international sammenslutning af juridisk separate, uafhængige medlemsfirmaer, der består af skatte- og juraeksperter fra hele verden. Andersen Global blev etableret af det amerikanske medlemsfirma Andersen Tax LLC i 2013 og har nu over 4.500 eksperter verden rundt og er repræsenteret på mere end 142 steder via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20190523005821/da/
Contact:
Megan Tsuei Andersen Tax 415-764-2700
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
